Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tubulin beta chain, class I is a major cytoskeletal protein that forms heterodimers with alpha-tubulin to assemble microtubules, which are essential for cell division, structural integrity, intracellular trafficking, and other key cellular processes. As a core structural component, beta-tubulin class I is expressed in a variety of tissues and is notably implicated in cancer, where its altered expression can mediate drug resistance. It is directly targeted by a spectrum of chemotherapy agents that disrupt or stabilize microtubule dynamics, making it one of the best-characterized molecular targets in cell biology and pharmacology[3][4][5][6][7].
Inhibition of microtubule polymerization (prevents assembly, e.g., vinca alkaloids, colchicine) Stabilization of microtubules (prevents disassembly, e.g., taxanes)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin beta chain, class I (TUBB).